20/20 Biolabs Inc Dossier - Source-backed chat

20/20 Biolabs Inc

AIDXNASDAQ

SectorHealth Care

IndustryMedical Devices

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.44Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $5.6M

Shares Outstanding 12.8M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

20/20 Biolabs Inc. (Nasdaq: AIDX) is an early market entrant in AI-powered, laboratory-based blood tests for early cancer and chronic disease detection. While the company's OneTest platform shows strong commercial momentum—particularly through state-funded firefighter screening programs in Maryland and Vermont—and has a clear long-term catalyst in the 2028 Medicare MCED reimbursement pathway, near-term risks warrant caution. The company faces severe liquidity pressures, heavy cash burn, and potential dilution from its Series E convertible preferred stock. Additionally, it is currently non-compliant with Nasdaq's $1.00 minimum bid price rule, with a deadline of January 13, 2027, to cure the deficiency. Given these structural and financial headwinds, a Hold recommendation is advised until commercial revenues scale sufficiently to reduce reliance on dilutive external financing.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$5.00

High · most bullish analyst$5.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0020%

The bear case materializes if the company fails to regain compliance with Nasdaq's minimum bid price rule by January 13, 2027, leading to delisting to the OTC markets. Commercial revenues fail to rebound from the Q1 2026 decline, and the cash runway is exhausted before Q1 2027. Streeterville Capital resumes aggressive conversions of Series E preferred stock after the 120-day standstill expires, causing massive equity dilution. Clinical trials or regulatory hurdles delay FDA authorization, closing off the 2028 Medicare reimbursement pathway.

Base CaseCentral scenario

$5.0050%

Matches the consensus mean

The base case assumes steady but gradual commercial expansion. Firefighter screening programs provide a stable baseline of revenue, and Q2 2026 MCED revenue grows by at least 30% year-over-year. However, cash burn remains high, requiring continued reliance on structured financing. The company manages to regain Nasdaq compliance, potentially through a reverse stock split or temporary price recovery, but faces moderate dilution from Series E conversions. Progress toward FDA authorization and Medicare reimbursement remains on track but slow.

Bull CaseUpside scenario

$5.0030%

The bull case is driven by rapid commercial adoption of OneTest for Cancer and OneTest for Longevity. State-funded screening contracts (such as the $520,000 Maryland program and the Vermont firefighter initiative) scale rapidly, driving Q2 2026 and full-year revenues to record highs. The company successfully leverages real-world data from over 35,000 tested firefighters to secure FDA authorization and subsequent Medicare reimbursement by 2028. Furthermore, the company successfully cures its Nasdaq bid-price deficiency without highly dilutive reverse splits, and the Series E preferred stock is converted under favorable terms.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pioneering AI-powered multi-cancer early detection (MCED) and longevity testing platforms (OneTest) with competitive performance against expensive ctDNA-based tests.
Strong commercial traction in high-risk niche markets, notably state-funded cancer screening programs for firefighters in Maryland and Vermont.
Clear long-term regulatory and reimbursement catalyst via the newly established statutory Medicare coverage pathway for MCED tests starting in 2028.

Key Investment Risks

Severe financial distress characterized by low cash reserves ($4.2 million as of March 31, 2026), high cash burn, and persistent operating losses.
Significant risk of equity dilution from the conversion of up to $40 million of Series E convertible preferred stock, despite a temporary 120-day standstill agreement.
Regulatory and compliance risks, including current non-compliance with Nasdaq's $1.00 minimum bid price requirement and the need to obtain FDA authorization and CMS approval for Medicare coverage.

Thesis Invalidation Triggers

Delisting from the Nasdaq Capital Market due to failure to regain compliance with the $1.00 minimum bid price rule by January 13, 2027.
Failure of Q2 2026 MCED revenue to achieve the projected 30% year-over-year growth, indicating a failure of commercial scaling.
An Event of Default under the Series E Preferred Stock transaction documents, terminating the Streeterville standstill agreement and triggering immediate dilutive conversions.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.